Liquisolid Compacts: A Promising Approach for Solubility Enhancement

Pawar, Janardhan D; Jagtap, Rajesh; Doijad, Rajendra; Pol, Savitri; Desai, J R; Jadhav, Vijay; Jagtap, Sneha

doi:10.22270/jddt.v7i4.1466

Cited by 10 publications

(7 citation statements)

References 3 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A mathematical model was introduced by Spireas et al to design the formulation of liquisolid system [6,13]. In the present work, propylene glycol and polysorbate 80 were used as liquid vehicles, Eudragit ® RL and Aerosil ®…”

Section: Application Of Mathematical Model For the Design Of Liquisolmentioning

confidence: 99%

“…After the carrier powder is saturated with the liquid medication, a liquid layer formed on the particle surface is adsorbed by the coating material. Consequently, a dry, free-flowing, and compressible powder is obtained [6]. This technology is initially used in the purpose of improving drug solubility of poorly water-soluble drugs by using water-soluble polymer [7][8][9].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Development of Liquisolid Formulation for Improved Sustained Release of Propranolol Hydrochloride

et al. 2021

View full text Add to dashboard Cite

Objective: The aim of this study was to develop a liquisolid formulation of propranolol hydrochloride to obtain an improved sustained release profile by varying the ratio of liquid vehicles. Methods: In this study, propranolol hydrochloride (PPH) was dispersed in the combination of propylene glycol and polysorbate 80, as the liquid vehicles, with different ratios. Eudragit® RL and Aerosil® were used as carrier and coating materials, respectively, to produce a dry and free-flowing powder. In addition, HPMC was used to amplify the retardation effect. The prepared formulations were evaluated for its physicochemical properties, including loss on drying, flow rate, angle of repose calculation, drug content analysis, FT-IR spectroscopy, as well as dissolution studies. The obtained dissolution profiles were subsequently fitted to the mathematical model in order to determine the drug kinetics. Results: The results show that all formulations performed dry and free-flowing granules containing PPH in the range of 7-9%. Furthermore, all the prepared formulations were able to sustain the drug release for a total of 8 h in two different dissolution media, namely simulated gastric fluid and simulated intestinal fluid. F4 containing propylene glycol and polysorbate 80 (1:2) possessed the lowest drug release rate. It was also obtained that F1 and F3 followed first-order kinetics while F2, F4, and F5 complied with the Higuchi model. Conclusion: Overall, there was no difference in all the dissolution profiles based on the calculation of the difference and similarities factor.

show abstract

Section: Application Of Mathematical Model For the Design Of Liquisolmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Development of Liquisolid Formulation for Improved Sustained Release of Propranolol Hydrochloride

et al. 2021

View full text Add to dashboard Cite

show abstract

“…For attaining good flow properties trial and error methods were used i.e. changing the carrier: coating material ratio from 50:1 Tween 80 MCC and colloidal silica Ibuprofen 27 PEG 400 MCC and colloidal silica Ketoprofen 28 PEG 400 lactose and silica gel Naproxen 29 Cremophor EL, Synperonic PE/L61 and PEG-200 MCC and colloidal silica Valsartan 30 Propylene glycol MCC and colloidal silica Etoricoxib 31 PEG 400 MCC and colloidal silica Famotidine 32 Propylene glycol MCC and colloidal silica Fenofibrate 33 Propylene glycol MCC and colloidal silica Fenofibrate 34 PEG 400 MCC and colloidal silica diclofenac sodium 35 PEG 400 MCC and colloidal silica…”

Section: Preparation Of Liquid Solid Compactsmentioning

confidence: 99%

A Promising Technique to Improve the Solubility by Liquisolid Compaction Technology

Naik¹,

Sunder

Manchikanti

2018

J. Drug Delivery Ther.

View full text Add to dashboard Cite

About 60-70% of the drugs synthesized are poorly soluble and comes under BCS Class-II&IV. Now it is a challenging situation during the development of different dosage forms for pharmaceutical industries because solubility of the drug is the rate limiting step. Based on the solubility, the dissolution, bioavailability & therapeutic effect is dependent. To overcome this consequence a novel technique -Liquisolid compact is used by dissolving the poorly soluble drug in a non-volatile solvent that improves wettability & decreases the surface tension and ensures drug molecular dispersion in the formulation to increase the solubility of the drug. This admixture of drug loaded solution is blended with carrier adsorption & coating material (adsorption) that has free flowing and compressible powder properties.

show abstract

“…The oral bioavailability of drugs plays a significant role in the drug dissolution process in the gastrointestinal tract. [4] Due to low aqueous solubility and restricted intestinal permeability, around 40% of newly discovered drug encounters significant biopharmaceutical difficulties, resulting in poor drug absorption and minimal ORIGINAL ARTICLE therapeutic benefits. [5] Various methods have been employed to increase the dissolution rate of rosuvastatin calcium which involves SNEDDS, [6] nanoparticles, [7] SEDDS, [8] and niosomes.…”

Section: Introductionmentioning

confidence: 99%

Untitled

2021

IJGP

View full text Add to dashboard Cite

Aim:The main aim of the investigation was to enhance the dissolution rate of rosuvastatin calcium by formulating it as a liquisolid tablet and compare with a marketed formulation. Materials and Methods: Rosuvastatin calcium liquisolid tablets were formulated using propylene glycol and PEG 400 as a non-volatile liquid vehicle, Avicel pH 102, and Aerosil 200 as carrier and coating material, sodium starch glycolate as superdisintegrant. The formulated rosuvastatin calcium liquisolid tablet was evaluated for pre-compression parameters to increase the flow property of the drug and post-compression parameters. The in vitro drug release characteristics of rosuvastatin calcium liquisolid formulation were performed using pH 6.8 phosphate buffer as dissolution media and compared with the marketed formulation and direct compressible tablet. The analytical study of drug excipient interaction of rosuvastatin calcium was characterized by Fourier transform infrared (FT-IR) and DSC analysis. Results and Discussion:The solubility profile of rosuvastatin calcium in propylene glycol and PEG 400 was found to be higher than the other non-volatile liquid vehicle. The formulated rosuvastatin calcium liquisolid tablet (F1, F2, F3, F5, and F6) has accepted flow properties. The post-compression evaluation data of thickness, weight variation, hardness, friability, disintegration, drug content comply with the Indian Pharmacopoeia limits. Among the eight liquisolid formulations (F2) showed the highest percentage of drug release 99% at 60 min, whereas, marketed formulation showed 86.2% of drug release at 60 min. The FT-IR analysis revealed that there is no interaction between drug and excipient. DSC analysis of liquisolid formulation (F2) confirmed the conversion of crystalline state to amorphous form. A significant difference (P = 0.002 < 0.05) was found in the dissolution rate of the best formulation (F2) when compared with the marketed formulation. Conclusion: It can be concluded from the research work that liquisolid compact technique is a promising method of approach for the dissolution rate enhancement of rosuvastatin calcium due to increased wetting property and more drug surface exposed to the dissolution medium.

show abstract

Liquisolid Compacts: A Promising Approach for Solubility Enhancement

Cited by 10 publications

References 3 publications

Development of Liquisolid Formulation for Improved Sustained Release of Propranolol Hydrochloride

Development of Liquisolid Formulation for Improved Sustained Release of Propranolol Hydrochloride

A Promising Technique to Improve the Solubility by Liquisolid Compaction Technology

Untitled

Contact Info

Product

Resources

About